Mikhail (Misha) Blagosklonny, M.D., Ph.D. is a founder and Editor-in-Chief at Oncotarget and Aging, an Editor-in-Chief at Oncoscience, and an editor at Genes and Cancer. These four journals are part of the Impact Journals family of scientific publications, based out of Orchard Park, New York.
Dr. Blagosklonny graduated with his Doctor of Medicine and Doctorate from First Pavlov State Medical University in St. Petersburg, Russia. He then moved to the United States, where he became well-known for his contributions in cancer and aging research.
Dr. Blagosklonny has published dozens of experimental and theoretical papers focusing on: 1) the hyperfunction theory of aging and, 2) the selective killing of cancer cells with deregulated cell cycle or drug resistance by exploiting their resistance. The hyperfunction theory has led to the rediscovery of Rapamycin as a well-tolerated anti-aging drug. To learn more about this venture, visit Rapamycin Press.
Oncotarget.org publishes weekly articles describing new and trending research papers published by Oncotarget—an open access biomedical journal dedicated to the publishing of the latest oncology-focused, peer-reviewed research papers.
For those interested in learning more about Oncotarget or in contacting the Journal, visit Oncotarget.com.
For media inquiries, please contact firstname.lastname@example.org.